Evidence map›Paper›PMID 24965456›Full record

ArticleJournal of virology2014

Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.

Madelyn R Schmidt, Lori W McGinnes-Cullen, Sarah A Kenward, Kristin N Willems, Robert T Woodland, Trudy G Morrison

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Meeting report VLPNPV: Session 3: Immune responses.Human vaccines & immunotherapeutics · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Madelyn R SchmidtDepartment of Microbiology and Physiological Systems/Program in Immunology and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Lori W McGinnes-CullenDepartment of Microbiology and Physiological Systems/Program in Immunology and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Sarah A KenwardDepartment of Microbiology and Physiological Systems/Program in Immunology and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Kristin N WillemsDepartment of Microbiology and Physiological Systems/Program in Immunology and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Robert T WoodlandDepartment of Microbiology and Physiological Systems/Program in Immunology and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Trudy G MorrisonDepartment of Microbiology and Physiological Systems/Program in Immunology and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA trudy.morrison@umassmed.edu.
University of Massachusetts Chan Medical School · US

Funding

Technologies for Human Cellular ImmunologyU19AI057319 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LIBRATY, DANIEL H. · 2003 to 2013
$34.4M
PILOT AND FEASIBILITY PROGRAMP30DK032520 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 1986 to 2010
$14.6M
TRAINING IN IMMUNOLOGY (COMPETITIVE RENEWAL OF AI07439)T32AI007349 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J. · 1989 to 2024
$4.5M
IMMUNODEFICIENCIES THAT IMPAIR LYMPHOCYTE SURVIVALR01AI041054 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WOODLAND, ROBERT THOMAS · 1997 to 2009
$2.6M
HIV vaccine development using humanized miceR01AI084800 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WOODLAND, ROBERT THOMAS · 2009 to 2013
$2.0M
Humoral Immune Responses to Virus-like Particle Vaccine Candidates for RSVR56AI093791 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MORRISON, TRUDY G. · 2011 to 2011
$411k
Immunodeficiencies that impair lymphocyte survivalR21AI041054 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WOODLAND, ROBERT THOMAS · 2003 to 2003
$278k
NIAID NIH HHS AI041054NIAID NIH HHS AI057319NIAID NIH HHS AI084800NIAID NIH HHS AI093791NIAID NIH HHS R01 AI041054NIAID NIH HHS R01 AI084800NIAID NIH HHS R21 AI041054NIAID NIH HHS R56 AI093791NIAID NIH HHS T32 AI007349NIAID NIH HHS U19 AI057319NIDDK NIH HHS DK32520NIDDK NIH HHS P30 DK032520
6 · The paper itself

Abstract

unlabelledImmunization with virus-like particles (VLPs) containing the Newcastle disease virus (NDV) core proteins, NP and M, and two chimera proteins (F/F and H/G) containing the respiratory syncytial virus (RSV) F- and G-protein ectodomains fused to the transmembrane and cytoplasmic domains of NDV F and HN proteins, respectively, stimulated durable RSV-neutralizing antibodies, F-protein-specific long-lived, bone marrow-associated plasma cells (LLPCs), and B cell memory, in striking contrast to RSV infection, which did not (M. R. Schmidt, L. W. McGinnes, S. A. Kenward, K. N. Willems, R. T. Woodland, and T. G. Morrison, J. Virol. 86:11654-11662, 2012). Here we report the characterization of a VLP with an RSV F-protein ectodomain fused to the NDV F-protein heptad repeat 2 (HR2), transmembrane, and cytoplasmic domain sequences, creating a chimera with two tandem HR2 domains, one from the RSV F protein and the other from the NDV F-protein ectodomain (F/HR2F). The F/HR2F chimera protein was efficiently assembled into VLPs along with the H/G chimera protein. This VLP (VLP-H/G+F/HR2F) stimulated anti-F-protein and anti-G-protein IgG, durable RSV-neutralizing antibodies, and anti-RSV F-protein-secreting LLPCs. However, the subtypes of anti-F-protein IgG induced were different from those elicited by VLPs containing the F/F chimera (VLP-H/G+F/F). Most importantly, VLP-H/G+F/HR2F did not induce RSV F-protein-specific B cell memory, as shown by the adoptive transfer of B cells from immunized animals to immunodeficient animals. The VLP did, however, induce B cell memory specific to the RSV G protein. Thus, the form of the F protein has a direct role in inducing anti-F-protein B cell memory. IMPORTANCE: The development of vaccines for respiratory syncytial virus (RSV) is hampered by a lack of a clear understanding of the requirements for eliciting protective as well as durable human immune responses to virus antigens. The results of this study indicate that the form of the RSV F protein has a direct and significant impact on the type of anti-F-protein IgG antibodies induced and the generation of F-protein-specific memory. Identification of the conformation of the RSV F protein that most effectively stimulates not only LLPCs and but also memory B cells will be important in the future development of RSV vaccines.

Indexed as

Immunologic MemoryAnimalsAntibodies, NeutralizingAntibodies, ViralB-LymphocytesGenetic VectorsImmunoglobulin GMice, Inbred BALB CNeutralization TestsNewcastle disease virusRecombinant Fusion ProteinsRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus VaccinesVaccines, SyntheticVaccines, Virus-Like ParticleViral Fusion ProteinsAntibodies, NeutralizingAntibodies, ViralF protein, human respiratory syncytial virusImmunoglobulin GRecombinant Fusion ProteinsRespiratory Syncytial Virus VaccinesVaccines, SyntheticVaccines, Virus-Like ParticleViral Fusion Proteins

Identifiers

PMID24965456
PMCPMC4136311
OpenAlexW2170271017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.